Breaking Finance News

OHR Pharmaceutical Inc (NASDAQ:OHRP) has been downgraded to Hold in a statement by Zacks Investment Research earlier today.

Boasting a price of $2.77, OHR Pharmaceutical Inc (NASDAQ:OHRP) traded -0.36% lower on the day. With the last stock price close down -6.57% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the date range. OHR Pharmaceutical Inc has recorded a 50-day average of $2.74 and a two hundred day average of $2.92. Volume of trade was down over the average, with 52,172 shares of OHRP changing hands under the typical 74,869

Zacks Investment Research has downgraded OHR Pharmaceutical Inc (NASDAQ:OHRP) to Hold in a statement released on 10/05/2016.

Performance Chart

OHR Pharmaceutical Inc (NASDAQ:OHRP)

With a total market value of $0, OHR Pharmaceutical Inc has with a 52 week low of $2.44 and a 52 week high of $6.56 .

Brief Synopsis On OHR Pharmaceutical Inc (NASDAQ:OHRP)

Ohr Pharmaceutical, Inc. is a pharmaceutical company. The Company is focusing on the development of therapeutics and delivery technologies for the treatment of ocular disease. The Company's development pipeline consists of various programs and indications at various stages of development. The Company's clinical program, OHR-102 eye drops, is a therapeutic product that provides a non-invasive therapy to improve vision outcomes without requiring multiple injections per office visit. The Company focuses on OHR-102 eye drops, which is given in combination with Lucentis injections, for the treatment of retinal diseases, including wet-age-related macular degeneration (AMD), retinal vein occlusion and proliferative diabetic retinopathy. The Company's product pipeline also includes SKS Sustained Release Ocular Drug Delivery Platform Technology, Animal Model for Dry-AMD and Non-Ophthalmology Assets. OHR-102 is a small molecule anti-angiogenic drug with an intracellular mechanism of action.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *